Compare Stocks → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:OKYONYSE:TRXNASDAQ:VIRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOKYOOKYO Pharma$1.42-4.4%$1.45$0.92▼$3.25$41.06M0.03140,691 shs3,250 shsTRXTRX Gold$0.45-0.5%$0.41$0.31▼$0.60$125.54M0.59331,111 shs286,925 shsVIRXViracta Therapeutics$0.82+2.5%$0.95$0.43▼$2.38$32.20M0.95103,341 shs20,918 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOKYOOKYO Pharma-1.97%+2.01%+6.43%+15.50%-13.37%TRXTRX Gold+1.71%-1.84%-1.42%+38.59%-16.61%VIRXViracta Therapeutics-1.25%-2.43%-21.56%+29.47%-19.99%Biden to Launch “FedNOW” [Move Your Money Now] (Ad)Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOKYOOKYO Pharma2.2934 of 5 stars3.55.00.00.00.01.70.6TRXTRX Gold3.3443 of 5 stars3.50.00.00.02.90.03.1VIRXViracta Therapeutics0.9845 of 5 stars3.52.00.00.00.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOKYOOKYO Pharma3.00Buy$7.00391.50% UpsideTRXTRX Gold3.00Buy$1.58249.92% UpsideVIRXViracta Therapeutics3.00Buy$7.00753.66% UpsideCurrent Analyst RatingsLatest VIRX, TRX, IXI, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024VIRXViracta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.004/16/2024TRXTRX GoldAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $1.754/16/2024TRXTRX GoldHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.30 ➝ $1.404/16/2024VIRXViracta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/ATRXTRX Gold$38.32M3.28$0.01 per share34.10$0.22 per share2.05VIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)TRXTRX Gold$2.25M$0.0145.065.63N/A0.70%-1.66%-1.18%N/AVIRXViracta Therapeutics-$51.06M-$1.32N/AN/AN/AN/A-172.32%-71.40%5/13/2024 (Estimated)Latest VIRX, TRX, IXI, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/12/2024Q2 2024TRXTRX GoldN/A$0.01+$0.01N/A$9.40 million$7.98 million 3/7/2024Q4 2023VIRXViracta Therapeutics-$0.30-$0.35-$0.05-$0.35N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOKYOOKYO PharmaN/AN/AN/AN/AN/ATRXTRX GoldN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOKYOOKYO PharmaN/AN/AN/ATRXTRX GoldN/A0.930.59VIRXViracta TherapeuticsN/A1.431.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOKYOOKYO Pharma2.97%TRXTRX Gold1.06%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipOKYOOKYO Pharma40.46%TRXTRX Gold2.25%VIRXViracta Therapeutics7.42%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionableTRXTRX Gold130278.92 million272.64 millionOptionableVIRXViracta Therapeutics4039.27 million36.36 millionOptionableVIRX, TRX, IXI, and OKYO HeadlinesSourceHeadlineViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conferenceglobenewswire.com - May 7 at 4:05 PMDay One wins FDA nod for brain cancer therapy, Ojemdamsn.com - April 23 at 3:26 PMPromising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeuticsmarkets.businessinsider.com - April 18 at 7:46 AMAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)markets.businessinsider.com - April 17 at 12:57 PMAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)markets.businessinsider.com - April 16 at 3:51 PMViracta Eyes FDA Accelerated Approval Path for Nana-val in EBV-Positive PTCLprecisionmedicineonline.com - April 16 at 10:50 AMWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?msn.com - April 15 at 1:27 PMViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphomaglobenewswire.com - April 15 at 8:00 AMViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwanglobenewswire.com - April 1 at 8:30 AMViracta Therapeutics CFO and COO Dan Chevallard resignsinvesting.com - March 22 at 9:44 PMBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financialsmarkets.businessinsider.com - March 12 at 2:39 PMVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023msn.com - March 8 at 9:38 AMViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 7 at 4:05 PMViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trialglobenewswire.com - February 29 at 8:00 AMVIRX Mar 2024 2.500 callfinance.yahoo.com - February 17 at 9:42 AMViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:23 PMViracta Therapeutics Provides Clinical Update and Outlook for 2024finance.yahoo.com - January 4 at 10:14 AMTaking a Closer Look At Viracta Therapeutics Inc (VIRX) Following Its Recent Tradeknoxdaily.com - January 1 at 8:28 AMViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:49 PMViracta gets orphan drug status for Nana-val for EBV tumorsmsn.com - December 12 at 3:20 PMViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinomafinance.yahoo.com - December 12 at 10:19 AMViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levelsfinance.yahoo.com - December 4 at 9:39 AMViracta Therapeutics Inc VIRXmorningstar.com - November 18 at 2:25 PMA company insider recently sold 3,512 shares of Viracta Therapeutics Inc [VIRX]. Should You Sale?knoxdaily.com - November 9 at 11:39 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsOKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.TRX GoldNYSE:TRXTRX Gold Corporation engages in the exploration, development, and production of mineral property interests in the United Republic of Tanzania. The company primarily explores for gold deposits. It holds interests in the Buckreef gold project that comprises a single Special Mining License covering an area of 16.04 square kilometers and 12 Prospecting Licenses covering 98.19 square kilometers located in north-central Tanzania. The company was formerly known as Tanzanian Gold Corporation and changed its name to TRX Gold Corporation in May 2022. TRX Gold Corporation was incorporated in 1990 and is based in Oakville, Canada.Viracta TherapeuticsNASDAQ:VIRXViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
